Dr Reddy's Generic Semaglutide to Slash Weight-Loss Drug Prices by 2026

• Dr Reddy's Laboratories plans to launch a generic version of semaglutide in March 2026, potentially lowering weight-loss drug costs significantly.
• The move could disrupt a market currently dominated by expensive imported brands like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.
• India's anti-obesity drug market has seen rapid growth, with Mounjaro becoming the highest-selling drug, clocking over Rs 496 crore in sales.
• High therapy costs have limited access to these drugs, despite rising demand from both diabetics and younger urban patients.
• Generic entry is expected to increase affordability and accessibility, preventing patients from resorting to unsafe 'Jugaad' techniques for dosage.